BioMedTracker is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Informa
Menu

Report Library

All Reports
Datamonitor Healthcare Prostate Cancer KOL Interview

April 12, 2018

The interview covers the current and future treatment of prostate cancer, with special interest paid to the use of already approved and pipeline therapies in earlier treatment lines, including metastatic hormone-sensitive and non-metastatic castration-resistant prostate cancer. The interview focuses on the valuable endpoints utilised in Phase III clinical trials, the requirement for post-launch sequencing studies, and the key factors which will likely determine the relevant uptake of therapies in the same patient population.

If you are a KOL Insight Subscriber, please access the interview (link) from our KOL Insight portal (Subscribers only).

Biomedtracker will be offering KOL Reports and Physician Pulse Surveys for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (858) 200-2357.

Disease Group Covered: Oncology
Back to the top Back to the top